Crohn's patients can now start Skyrizi at home instead of by IV
Published
The FDA approved an under-the-skin starting dose of AbbVie's Skyrizi, given with a wearable injector, for adults with moderate to severe Crohn's disease. In a trial, 56% reached remission at 12 weeks versus 30% on placebo. IV starts remain an option; talk to your gastroenterologist.
Source: HCPLive
This is a plain-language summary. Read the original source for full details.